Trial Profile
Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Methylprednisolone
- Indications Macrophage activation syndrome
- Focus Adverse reactions
- Acronyms MAS
- 26 Feb 2024 Planned End Date changed from 15 Dec 2023 to 30 Apr 2024.
- 16 Oct 2023 Planned End Date changed from 1 Oct 2023 to 15 Dec 2023.
- 17 Aug 2023 Planned End Date changed from 1 Aug 2023 to 1 Oct 2023.